Stockscreener 앱 받기
18.59
1.48%
-0.28
전일 마감가:
$18.87
열려 있는:
$19.05
하루 거래량:
661.10K
Relative Volume:
0.73
시가총액:
$565.67M
수익:
$17.16M
순이익/손실:
$-163.62M
주가수익비율:
-3.0576
EPS:
-6.08
순현금흐름:
$-121.61M
1주 성능:
-12.39%
1개월 성능:
+10.13%
6개월 성능:
-50.79%
1년 성능:
-27.07%
1일 변동 폭
$18.08
$19.16
1주일 범위
$18.08
$21.57
52주 변동 폭
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
18.59 | 565.67M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7%What's Next? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update - MarketBeat
Q1 Earnings Forecast for AnaptysBio Issued By HC Wainwright - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 8.6% in January - Defense World
What is HC Wainwright’s Forecast for AnaptysBio Q1 Earnings? - Armenian Reporter
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $51.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Up 16.5% After Analyst Upgrade - MarketBeat
Q1 Earnings Estimate for AnaptysBio Issued By HC Wainwright - Defense World
AnaptysBio (NASDAQ:ANAB) Given New $51.00 Price Target at Wells Fargo & Company - Armenian Reporter
Wedbush Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? - MSN
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright - MSN
When the Price of (ANAB) Talks, People Listen - Stock Traders Daily
Wells Fargo & Company Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $51.00 - Defense World
What Analysts Were Expecting After AnaptysBio Inc (NASDAQ: ANAB) rose 19.44% - Stocks Register
AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected - Simply Wall St
Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline - TipRanks
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral By Investing.com - Investing.com Canada
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data - Yahoo Finance
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - Yahoo Finance
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment - MSN
Rosnilimab shows promise in rheumatoid arthritis trial By Investing.com - Investing.com Canada
Rosnilimab shows promise in rheumatoid arthritis trial - MSN
Vanda and AnaptysBio link for generalised pustular psoriasis therapy - MSN
Anaptys stock surges on trial readout (update) (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio rockets on rosnilimab data - The Pharma Letter
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial - Yahoo Finance
AnaptysBio climbs on arthritis drug trial data - TradingView
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday - Benzinga
AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial - Fierce Biotech
AnaptysBio stock soars on positive RA trial results - MSN
AnaptysBio Announces Promising Phase 2b RENOIR Trial Results - TipRanks
Anaptys Announces Rosnilimab Achieves Positive Results in Ra Phase 2B Trial and Highest Ever Reported Cdai Lda Response over 6 Months - Marketscreener.com
Anaptys surges as arthritis therapy succeeds in mid-stage trial - MSN
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise - Marketscreener.com
Anaptys stock surges on trial readout (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio stock soars on positive RA trial results By Investing.com - Investing.com Australia
Anaptys Announces Rosnilimab Achieved Positive Results In RA Phase 2B Trial -February 12, 2025 at 07:44 am EST - Marketscreener.com
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - The Manila Times
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint - TipRanks
Anaptys Announces Rosnilimab Achieved Positive Results in - GlobeNewswire
Rosnilimab Phase 2b Trial Achieves Record-Breaking 69% Response Rate in Rheumatoid Arthritis | ANAB Stock News - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket - Benzinga
AnaptysBio (ANAB) Stock Sees Strong Gains In Extended Session - Stocks Telegraph
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anaptysbio Inc 주식 (ANAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
Dec 30 '24 |
Buy |
12.92 |
65,184 |
842,060 |
7,860,180 |
| EcoR1 Capital, LLC | Director |
Dec 31 '24 |
Buy |
12.93 |
13,268 |
171,513 |
7,873,448 |
| EcoR1 Capital, LLC | Director |
Jan 02 '25 |
Buy |
12.95 |
6,646 |
86,070 |
7,880,094 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Option Exercise |
6.93 |
10,000 |
69,300 |
11,950 |
| RENTON HOLLINGS | Director |
Nov 29 '24 |
Sale |
25.00 |
10,000 |
250,000 |
1,950 |
0.27%
3.05%
자본화:
|
볼륨(24시간):